Theriva™ Biologics获欧洲药品管理局(EMA)关于VCN-01治疗转移性胰腺导管腺癌(PDAC)三期临床试验设计的积极科学建议

美股速递
Dec 29, 2025

Theriva™ Biologics公司宣布,已获得欧洲药品管理局(EMA)就其候选药物VCN-01用于治疗转移性胰腺导管腺癌(PDAC)的三期临床试验设计所提出的积极科学建议。这一进展标志着VCN-01在临床开发道路上迈出了关键一步,为后续试验的顺利开展奠定了坚实基础。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10